Sign in →

Test Code DMTBR Mycobacterium tuberculosis Complex, Molecular Detection of Drug Resistance Markers, Next-Generation Sequencing


Ordering Guidance


This test is used to identify the drug resistance variants in an M tuberculosis complex culture isolate.



Shipping Instructions


1. For shipping information see Infectious Specimen Shipping Guidelines

2. Place specimen in a large infectious container (T146) and label as an etiologic agent/infectious substance.



Necessary Information


Specimen source and organism identification are required.



Specimen Required


Supplies: Infectious Container, Large (T146)

Specimen Type: Mycobacterium tuberculosis complex isolate growing in pure culture

Container/Tube:

Preferred: Solid slant medium (eg. Middlebrook 7H10, 7H11 or Lowenstein Jensen agar)

Acceptable: Broth medium (eg. Mycobacteria Growth Indicator Tube, 7H9 broth, BACT/ALERT MP or VersaTREK bottle). Note: Broth specimens will require subculture which will delay results.

Specimen Volume:

Solid slant medium: Isolate with visible growth

Broth medium: Greater than or equal to 3 mL of broth culture

Collection Instructions:

1. Organism must be in pure culture, actively growing. Do not submit mixed cultures.

2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.

3. Turnaround time for results may be delayed if subculture is needed to ensure purity.


Testing Algorithm

Next-Generation sequencing (NGS) of Mycobacterium tuberculosis complex isolates is performed followed by evaluation of selected genes of interest for the presence of well-characterized, drug resistance-conferring variants.

Method Name

Next-Generation Sequencing (NGS)

Specimen Type

Varies

Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time
Varies Ambient (preferred)
  Refrigerated 

Reject Due To

Agar plate Reject
Mixed culture Reject

Day(s) Performed

Monday through Friday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.